Microtubule inhibitor-based antibody–drug conjugates for cancer therapy

The specificity of monoclonal antibodies represents a potential therapeutic advantage, but their use as single agents in oncology has proven limited to date. The development of antibody-drug conjugates (ADCs) takes advantage of the specificity of the monoclonal antibody and potent cytotoxic effect o...

Descripción completa

Detalles Bibliográficos
Autores principales: Klute, Kelsey, Nackos, Eleni, Tasaki, Shinsuke, Nguyen, Daniel P, Bander, Neil H, Tagawa, Scott T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259504/
https://www.ncbi.nlm.nih.gov/pubmed/25506226
http://dx.doi.org/10.2147/OTT.S46887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259504/
https://www.ncbi.nlm.nih.gov/pubmed/25506226
http://dx.doi.org/10.2147/OTT.S46887

Ejemplares similares